Ninepoint Partners LP Purchases New Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Ninepoint Partners acquired 19,763 shares of Edwards Lifesciences in the second quarter, valued at approximately $1.79 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds, resulting in a consensus “Moderate Buy” rating and an average price target of $100.27.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. However, company insiders sold 25,570 shares worth about $2.22 million during the quarter.

Ninepoint Partners LP acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 19,763 shares of the medical research company's stock, valued at approximately $1,788,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at $26,000. RMG Wealth Management LLC acquired a new position in Edwards Lifesciences during the first quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences during the fourth quarter valued at $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Mizuho raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price objective on the stock. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business's stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 25,570 shares of company stock worth $2,219,390. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $90.02 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The business's 50-day moving average price is $89.12 and its two-hundred day moving average price is $84.63. The company has a market capitalization of $51.83 billion, a P/E ratio of 51.74, a price-to-earnings-growth ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source